Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 182,953 | 17,447 | 25,816 | 57,027 | 0 |
| Cost of Goods | 12,826 | 1,593 | 955 | 2,075 | N/A |
| Gross Profit | 170,127 | 15,854 | 24,861 | 54,952 | N/A |
| Operating Expenses | 291,522 | 159,605 | 88,528 | 67,184 | 26,998 |
| Operating Income | -120,569 | -143,158 | -62,712 | -12,157 | -26,998 |
| Interest Expense | 7,849 | 3,346 | 2,199 | 0 | 0 |
| Other Income | 12,864 | 10,611 | 2,816 | -1,615 | 188 |
| Pre-tax Income | -115,554 | -135,893 | -62,095 | -13,772 | -26,810 |
| Income Tax | N/A | N/A | 4 | 55 | 1 |
| Net Income Continuous | -115,554 | -135,893 | -62,099 | -13,827 | -26,811 |
| Net Income | $-115,554 | $-135,893 | $-62,099 | $-13,827 | $-26,811 |
| EPS Basic Total Ops | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 |
| EPS Basic Continuous Ops | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 |
| EPS Diluted Total Ops | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 |
| EPS Diluted Continuous Ops | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 |
| EPS Diluted Before Non-Recurring Items | -3.07 | -4.62 | -2.52 | -0.67 | -4.32 |
| EBITDA(a) | $-123,075 | $-145,059 | $-63,393 | $-11,551 | $-26,752 |